- Home
- TGE vs CSTL Comparison
TGE vs CSTL Comparison
Compare TGE & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGE
- CSTL
- Stock Information
- Founded
- TGE 2023
- CSTL 2007
- Country
- TGE France
- CSTL United States
- Employees
- TGE N/A
- CSTL N/A
- Industry
- TGE Newspapers/Magazines
- CSTL Medical Specialities
- Sector
- TGE Consumer Discretionary
- CSTL Health Care
- Exchange
- TGE Nasdaq
- CSTL Nasdaq
- Market Cap
- TGE 436.6M
- CSTL 456.2M
- IPO Year
- TGE N/A
- CSTL 2019
- Fundamental
- Price
- TGE $6.50
- CSTL $19.66
- Analyst Decision
- TGE
- CSTL Strong Buy
- Analyst Count
- TGE 0
- CSTL 6
- Target Price
- TGE N/A
- CSTL $37.67
- AVG Volume (30 Days)
- TGE 243.6K
- CSTL 442.5K
- Earning Date
- TGE 01-01-0001
- CSTL 08-04-2025
- Dividend Yield
- TGE N/A
- CSTL N/A
- EPS Growth
- TGE N/A
- CSTL N/A
- EPS
- TGE 1.64
- CSTL N/A
- Revenue
- TGE $77,014,000.00
- CSTL $347,083,000.00
- Revenue This Year
- TGE N/A
- CSTL N/A
- Revenue Next Year
- TGE N/A
- CSTL $1.36
- P/E Ratio
- TGE $3.84
- CSTL N/A
- Revenue Growth
- TGE 81.03
- CSTL 38.43
- 52 Week Low
- TGE $5.60
- CSTL $15.45
- 52 Week High
- TGE $37.02
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- TGE N/A
- CSTL 55.46
- Support Level
- TGE N/A
- CSTL $19.21
- Resistance Level
- TGE N/A
- CSTL $20.26
- Average True Range (ATR)
- TGE 0.00
- CSTL 0.64
- MACD
- TGE 0.00
- CSTL -0.05
- Stochastic Oscillator
- TGE 0.00
- CSTL 60.34
About TGE The Generation Essentials Group Class A Ordinary Shares
The Generation Essentials Group is a media and entertainment company. Its publications L'Officiel and The Art Newspaper publish print editions in a total of nearly 28 countries and territories and digital contents. It operate in the movie production sector having produced various Asia-focused movies. It operate in three operating segments: media and entertainment segment, hotel operations, hospitality and VIP services segment and strategic investment segment. Key revenue is generated from strategic investment segment that is engage in proprietary investments and management of portfolio, including listed and unlisted equity shares investments and movie income right investments.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.